{
    "organizations": [],
    "uuid": "314a4d2a7f48203d0e256636e60fb2242a14150f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-glaukos-idose-travoprost-achieves/brief-glaukos-idose-travoprost-achieves-sustained-iop-reduction-and-favorable-safety-profile-in-12-month-interim-cohort-idUSFWN1P50GY",
    "ord_in_thread": 0,
    "title": "BRIEF-Glaukos' Idose Travoprost Achieves Sustained IOP Reduction And Favorable Safety Profile In 12-Month Interim Cohort",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 10 (Reuters) - Glaukos Corp:\n* GLAUKOS CORPORATION’S IDOSE™ TRAVOPROST ACHIEVES SUSTAINED IOP REDUCTION AND FAVORABLE SAFETY PROFILE IN 12-MONTH INTERIM COHORT\n* GLAUKOS CORP - COMPANY PREPARES TO COMMENCE PHASE III U.S. IND STUDY IN FIRST HALF OF 2018\n* GLAUKOS CORP - COMPANY BEGINS PROCESS FOR IDOSE TRAVOPROST REGULATORY APPROVAL IN EUROPE AND JAPAN\n* GLAUKOS CORP - CONDUCTED A PRODUCTIVE END-OF-PHASE II MEETING WITH FDA IN LATE 2017 ",
    "published": "2018-01-10T20:10:00.000+02:00",
    "crawled": "2018-01-11T12:34:02.017+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "glaukos",
        "corp",
        "glaukos",
        "corporation",
        "travoprost",
        "achieves",
        "sustained",
        "iop",
        "reduction",
        "favorable",
        "safety",
        "profile",
        "interim",
        "cohort",
        "glaukos",
        "corp",
        "company",
        "prepares",
        "commence",
        "phase",
        "iii",
        "ind",
        "study",
        "first",
        "half",
        "glaukos",
        "corp",
        "company",
        "begin",
        "process",
        "idose",
        "travoprost",
        "regulatory",
        "approval",
        "europe",
        "japan",
        "glaukos",
        "corp",
        "conducted",
        "productive",
        "ii",
        "meeting",
        "fda",
        "late"
    ]
}